B · Normal
[Sino Biopharmaceuticals: TQ-A3334 and TQA3605 were included in the breakthrough therapy drug program by CDE] On October 27, China Biopharmaceuticals announced on the Hong Kong Stock Exchange that its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. independently developed the national 1 The quasi-innovative drugs TQ-A3334 "Toll-like receptor 7 (TLR7) agonist" and TQA3605 "core protein allosteric modulator" have both been included in the breakthrough therapy drug program by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. The two innovative drugs respectively target the two major unmet needs in the treatment of chronic hepatitis B ("CHB"), namely functional cure and low viremia.
Comments